Gene

HLA-C

major histocompatibility complex, class I, C

Explore in graph →CI-GENE-00004454HGNC:4933 ENSG00000204525 NCBI 3107 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (2)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HLA-C COPY-NEUTRAL LOSS OF HETEROZYGOSITY1
Therapeutic Tumor Infiltrating Lymphocytes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID1899 A patient with metastatic colorectal cancer was enrolled in a phase 2 clinical trial (NCT01174121). 24 cultures of tumor-infiltrating lymphocytes were expanded from 3 lung metastasis resections. After… (full text at CIViC) PMID 27959684 · Tran et al., 2016 · Open in CIViC	civic
HLA-C Mutation1
(oncogenic)	Diffuse Large B-Cell LymphomaCURATED_BROADER	Oncogenic	E	Supports Oncogenicity	4	submitted

Cohorts

Alteration frequency by cohort (23)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved23 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Metastatic Biliary Tract Cancers (SUMMIT - Neratinib Basket Trial, 2022) biliary_tract_summit_2022	unmapped	Ssm	1	1	100%	39

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
· N Engl J Med · 2016 · PMID 27959684 · validated civic_curation pubmed